Ratings Arecor Therapeutics plc

Equities

Delayed London S.E. Other stock markets 03:08:51 2024-06-03 am EDT			5-day change	1st Jan Change
155 ^GBX	-2.52%		-3.12%	-15.07%

May. 21	Transcript : Arecor Therapeutics plc - Special Call
May. 20	Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins	CI

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.

	1st Jan change	Capi.	ESG Refinitiv
ARECOR THERAPEUTICS PLC	-15.07%	61.96M	-
MODERNA, INC.	+43.36%	54.63B	B-
IQVIA HOLDINGS INC.	-5.31%	39.92B	B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B	B-
CELLTRION, INC.	-12.56%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B	B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B	B+
BIO-TECHNE CORPORATION	+0.04%	12.16B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality